LM212 - Hearing AIDS: Auditory Effects of Antiretroviral Therapy

Thursday, March 31, 2022

2:30 PM – 3:30 PM CT

Location: 227

Earn 0.1 CEUs

Lead Presenter(s)

J. Riley DeBacker, AuD, PhD

Research Audiologist
VA RR&D National Center for Rehabilitative Auditory Research
Portland, Oregon

Disclosure: Financial Disclosures: I do not have any relevant financial relationships with anything to disclose.
Non-Financial Disclosures: I do not have any relevant non-financial relationships with anything to disclose.

PDF Slides

Presenter(s)

Breanna Langenek, B.A.

The Ohio State University
Pickerington, Ohio

Disclosure: Financial Disclosures: I do not have any relevant financial relationships with anything to disclose.
Non-Financial Disclosures: I do not have any relevant non-financial relationships with anything to disclose.
Eric C. Bielefeld, PhD

Professor
The Ohio State University
Dublin, Ohio

Disclosure: Financial Disclosures: I do not have any relevant financial relationships with anything to disclose.
Non-Financial Disclosures: I do not have any relevant non-financial relationships with anything to disclose.

Abstract:
Though antiretroviral drugs most commonly used to manage HIV are not included in most reviews of ototoxic drugs, an increasing number of recent studies have found auditory abnormalities in patients receiving antiretroviral therapy. Especially given the broadening implications of use for these drugs as HIV prophylaxis and in treating COVID-19, it is important for audiologists to be aware of reported effects of these drugs on hearing and balance. This presentation will include an overview of current antiretroviral uses before providing a review of current clinical and translational literature with suggestions for identifying, monitoring, and referring at-risk patients.

Learning Objectives:

Identify common antiretroviral drug names and elements of a case history that would indicate likely antiretroviral use.
Describe current research findings of auditory and vestibular symptoms following antiretroviral exposure.
Implement ototoxicity management practices for auditory surveillance of at-risk patients.